Dr. Cullen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-328-6841Fax+1 410-328-2578
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1987
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1983 - 1986
- Harvard Medical SchoolClass of 1983
Certifications & Licensure
- MD State Medical License 1987 - 2026
- DC State Medical License 1988 - 2004
- VA State Medical License 2001 - 2004
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Publications & Presentations
PubMed
- 351 citationsSurvival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trialMarshall R. Posner, Jochen H. Lorch, Olga Goloubeva, Ming Tan, Lisa M. Schumaker
Annals of Oncology. 2011-05-01 - 1148 citationsCisplatin and fluorouracil alone or with docetaxel in head and neck cancer.Marshall R. Posner, Diane Hershock, Cesar R. Blajman, Elizabeth Mickiewicz, Eric Winquist
The New England Journal of Medicine. 2007-10-25 - 6 citationsSatisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, NigeriaRebecca G. Nowak, Chinedu H Nnaji, Wuese Dauda, Andrew Mitchell, Oluwole Olayemi Olaomi
BMC Cancer. 2020-02-05
Press Mentions
- Dr. Kevin Cullen to Retire as Director of the University of Maryland Greenebaum Comprehensive Cancer Center in 2023January 17th, 2023
- Maryland Half Marathon and 5k Supports Cutting-Edge Research at University of Maryland Greenebaum Comprehensive Cancer CenterMay 26th, 2022
- Governor Hogan Announces Maryland Cancer Moonshot InitiativeMarch 31st, 2022
- Join now to see all
Grant Support
- Translational LaboratoryNational Cancer Institute2011
- Structural BiologyNational Cancer Institute2011
- Radiation Linear Shared ServiceNational Cancer Institute2011
- Protocol Specific ResearchNational Cancer Institute2011
- Protocol Review And Monitoring SystemNational Cancer Institute2011
- ProteomicsNational Cancer Institute2011
- Program LeadersNational Cancer Institute2011
- Planning And EvaluationNational Cancer Institute2011
- Pathology And BiorepositoryNational Cancer Institute2011
- Genomics - Shared ServicesNational Cancer Institute2011
- Flow CytometryNational Cancer Institute2011
- Data And Safety MonitoringNational Cancer Institute2011
- Clinical Research Shared ServicesNational Cancer Institute2011
- Biostatistics Shared ServiceNational Cancer Institute2011
- Animals Shared ServiceNational Cancer Institute2011
- AdministrationNational Cancer Institute2011
- University Of Maryland Greenebaum Cancer Center Support GrantNational Cancer Institute2008–2011
- Senior LeadershipNational Cancer Institute2008–2011
- Developmental FundsNational Cancer Institute2008–2011
- Program And Planning And EvaluationNational Cancer Institute2008–2010
- Prognostic Markers In Trials For Head And Neck CancerNational Cancer Institute2004–2005
- AP4 Planning For Targeted Drugs In Orphan CancersNational Cancer Institute2004
- Greenbaum Cancer Center, University Of MarylandNational Cancer Institute2001–2004
- Prognostic Markers In Trials For Head And Neck CancerNational Cancer Institute2003
- Midcareer Investigator AwardNational Cancer Institute2003
- Midcareer Investigator AwardNational Cancer Institute1999–2003
- Cancer Center Support GrantNational Cancer Institute2001–2002
- Clinical Oncology Research Career Development ProgramNational Cancer Institute2000–2002
- Insulin LIKE Growth Factor II In Breast CancerNational Cancer Institute1997–1999
- Predicting Chemotherapy Response In Head And Neck CancerNational Cancer Institute1997–1998
- Stromal/Epithelial Interactions In Breast CancerNational Cancer Institute1995
- Insulin-Like Growth Factor II In Breast CancerNational Cancer Institute1993–1995
- Stromal-Epithelial Interactions In Breast CancerNational Cancer Institute1991–1995
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: